Introduction
First described by Andral and Cruveilhier in 1830, Melanosis coli is a condition associated with the deposition of lipofuscin (not melanin as the name might imply) in the lamina propria of the large intestines. Historically, laxatives, primarily from the anthranoid group (ie, senna and rhubarb derivatives), are the main culprits. As these laxative supplements pass through the colon, they become active and cause cell death and apoptosis in the lining of the colon, eventually causing dark pigmentation of the colon. Diagnosis is typically made by colonoscopy. Discontinuing laxative use usually leads to the resolution of melanosis coli. Melanosis coli is not associated with an increased risk of colon cancer.[1]
Etiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Chronic laxative use, typically from the anthranoid group, causes Melanosis coli. Senna glycoside (senna) is the main causative laxative. As the laxative travels down the intestinal tract, it remains in its inactive form until it reaches the large intestine. Once in the large intestine, the molecules transform into their active form, leading to cell damage and death in the lining of the intestine, and apoptosis. As these cells undergo apoptosis, they create a dark pigment, lipofuscin, which eventually lines the large bowel. Eventually, these dead cells are taken up by macrophages. Melanosis coli can occur within only a few months of chronic laxative use.
Epidemiology
Anyone who abuses laxatives using them chronically is at risk of developing melanosis coli. It is typically seen in individuals aged 45 and older, but it has been reported in younger individuals. The rate increases with age. It is equally common in both sexes. Melanosis coli has also been seen in patients with chronic colitis who do not abuse laxatives.[1]
Pathophysiology
Melanosis coli is caused by chronic laxative use. Anthraquinones in laxatives have a direct toxic effect on the epithelial cells of the colon. When these laxative molecules turn into their active form in the large bowel, they can cause cell damage to the lining of the large bowel, leading to cell death. As the cells die, they create a dark pigment, which is lipofuscin deposition in the macrophages within the lamina propria, that is visible under colonoscopy. Melanosis coli is more common in the proximal bowel and much rarer in the distal colon. This is probably due to the difference in the macrophage distribution in the colonic wall. Once laxative use is halted, the dark pigmentations may resolve.[2]
Histopathology
Under microscopic evaluation, pigment-laden macrophages are typically seen on periodic acid–Schiff stain.
Toxicokinetics
Anthraquinones laxatives work in 3 ways:
- It stimulates the active transport of chloride into the gut, which in turn causes an osmotic gradient and pulls water into the gut lumen.
- It inhibits Na-K adenosine triphosphate (ATP)ase on the enterocytes, which further inhibits the reabsorption of water, sodium, and potassium, ultimately excreting it into the feces.
- It stimulates local prostaglandins, which stimulate peristalsis and decrease transit time through the bowel.
The adverse effects of senna and other stimulant laxatives include hypovolemia, leading to dizziness, palpitation, and syncope; miscarriages in women; and decreased absorption of oral medications due to uptake inhibition.
History and Physical
Typically melanosis coli causes no symptoms and is incidentally found during colonoscopy for other reasons. A detailed history should be focused on chronic laxative use, typically senna or cascara which contain anthraquinone, and a history of inflammatory bowel disease or colitis. These stimulant laxatives also can be found in over-the-counter herbal supplements and teas. Physical findings of melanosis coli are described through colonoscopy as black pigmentations lining the colonic mucosa.
Evaluation
Evaluation of melanosis coli is through colonoscopy. Biopsies should be taken to rule out true melanosis which may relate to more threatening diseases such as Peutz-Jegher Syndrome. No laboratory or imaging studies will help in making the diagnosis of melanosis coli. Characteristically, melanosis coli is most intense at the cecum and diminishes as it moves down the colon.[3][4]
Treatment / Management
The treatment of melanosis coli is to stop laxative use. Resolution takes up to a year.[2][4][5][6](B3)
Differential Diagnosis
It is important to rule out other causes before making the diagnosis of melanosis coli. Peutz-Jeghers syndrome, an autosomal dominant disorder that leads to numerous hamartomatous polyps in the bowel with distinct findings of melanin deposition in the skin and mucosa, may look like melanosis coli. Patients with this disease are at a 15-fold increase in developing colon cancer and must be ruled out before making the diagnosis of melanosis coli.
Prognosis
The prognosis is extremely positive in these patients. Melanosis coli will typically go away with causative laxative cessation. This can take up to one year. Rebound constipation can occur with laxative cessation. [7][1]
Complications
Some research has found a correlation between melanosis coli and colonic polyps. However, there is no consensus or evidence relating to an increased risk of colon cancer. There has been research supportive of melanosis coli and colorectal adenomas. Increased stimulant laxative use can cause electrolyte derangements due to the rapid transit through the bowel and lack of nutrition and water reabsorption. The most common is potassium imbalance which may be fatal.
Consultations
A gastroenterologist is needed to make the diagnosis by colonoscopy and exclude potential alternate causes. Dieticians may also be a benefit in cases of constipation.
Deterrence and Patient Education
It is important to note that laxative use is meant to be a temporary treatment for acute constipation in most patients. A healthy bowel regimen is essential for a healthy lifestyle, and one should not depend on stimulant laxatives such as senna. A diet hardy of fruits, vegetables, whole grains, and legumes will give the essential fiber needed to bulk stool and prevent constipation. Adequate hydration is another key step in having healthy bowel movements. One must keep in mind that other stimulants can cause constipation as well, such as coffee, energy drinks, fried food, excess carbohydrates, alcohol, red meat, and artificial sweeteners. Adequate physical exercise also stimulates the bowels allowing for peristalsis, rhythmic motion of the intestines, to take place and help with the transit of stool down the digestive tract. Adequate sleep helps the body regulate appropriate bowel health.
Pearls and Other Issues
Melanosis coli, in itself, is not a fatal disease and does not cause any known noticeable disease, but further research is ongoing. Diet alterations and increased physical exercise should be the mainstream and initial treatment for constipation. Oral fiber supplements such as psyllium should be used as the next step. Remember, stimulant laxative use was meant to be a short-term therapy for constipation and should not be used chronically except in patients with chronic motility issues or on constipating medications such as opioids.
Enhancing Healthcare Team Outcomes
Healthcare professionals including nurse practitioners and pharmacists should educate patients on the proper use of laxatives. Prolonged use of certain laxatives can result in melanosis coli. While the condition is benign, it often leads to unnecessary workup to rule out a malignancy, leading to higher healthcare costs. Patients who are constipated should be referred to a gastroenterologist to determine the cause. The dietitian should educate the patient on foods with a lower risk of constipation. Participating in regular exercise should also be encouraged.[8]
References
Wang S, Wang Z, Peng L, Zhang X, Li J, Yang Y, Hu B, Ning S, Zhang B, Han J, Song Y, Sun G, Nie Z. Gender, age, and concomitant diseases of melanosis coli in China: a multicenter study of 6,090 cases. PeerJ. 2018:6():e4483. doi: 10.7717/peerj.4483. Epub 2018 Mar 8 [PubMed PMID: 29568709]
Level 2 (mid-level) evidenceAbu Baker F, Mari A, Feldman D, Suki M, Gal O, Kopelman Y. Melanosis Coli: A Helpful Contrast Effect or a Harmful Pigmentation? Clinical medicine insights. Gastroenterology. 2018:11():1179552218817321. doi: 10.1177/1179552218817321. Epub 2018 Dec 4 [PubMed PMID: 30574001]
Lecomte T, Chautard R, Orain I. A melanosis coli associated with a large flat adenoma of the cecum. Clinics and research in hepatology and gastroenterology. 2019 Jun:43(3):228-229. doi: 10.1016/j.clinre.2018.10.006. Epub 2018 Nov 15 [PubMed PMID: 30447908]
Biernacka-Wawrzonek D, Stępka M, Tomaszewska A, Ehrmann-Jóśko A, Chojnowska N, Zemlak M, Muszyński J. Melanosis coli in patients with colon cancer. Przeglad gastroenterologiczny. 2017:12(1):22-27. doi: 10.5114/pg.2016.64844. Epub 2016 Dec 29 [PubMed PMID: 28337232]
Cohen GS. Melanosis Coli. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020 Jun:18(7):e71. doi: 10.1016/j.cgh.2019.03.032. Epub 2019 Mar 27 [PubMed PMID: 30928452]
Moeller J, Solomon R, Kiffin C, Ditchek JJ, Davare DL. Melanosis Coli: A Case of Mistaken Identity-A Case Report. The Permanente journal. 2019:23():18-063. doi: 10.7812/TPP/18-063. Epub [PubMed PMID: 30624202]
Level 3 (low-level) evidenceZimmer V, Emrich K. The Rusty Ring Sign Streamlining Flat Lesion Detection in Subtle Melanosis Coli. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018 Aug:16(8):A33. doi: 10.1016/j.cgh.2017.10.011. Epub 2018 Apr 9 [PubMed PMID: 29649462]
Modi RM, Hussan H. Melanosis Coli After Long-Term Ingestion of Cape Aloe. ACG case reports journal. 2016 Aug:3(4):e157 [PubMed PMID: 27921056]
Level 3 (low-level) evidence